BIOMAT Database Logo BIOMAT Database Logo

Isolation and characterization of simian immunodeficiency virus variants that are resistant to nonnucleoside reverse transcriptase inhibitors. 2000

Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
Discovery Research Laboratories, Shionogi & Co. Ltd., Osaka, Japan

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) act quite specifically on human immunodeficiency virus type 1 (HIV-1). In general, they are not effective on human immunodeficiency virus type 2 (HIV-2) or simian immunodeficiency virus (SIV). Only SIV strains from African green monkeys are sensitive to several NNRTIs. Here we isolated NNRTI- and 3TC-resistant SIVagm variants. Viruses resistant to delavirdine contained V112I and M231I substitutions, while those resistant to 3TC contained a M 185I substitution. These amino acids are highly conserved in HIV-1, HIV-2, SIVmac and SIVagm, and the M184I (M185I in SIVagm) substitution was observed in 3TC-resistant HIV-1 and SIVmac. The roles of the observed mutations in NNRTI-resistance of SIVagm and HIV-1 were further confirmed by site-directed mutagenesis. The present results have provided a new insight into the common mechanism of sensitivity of HIV- 1 and SIVagm to NNRTIs.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian
D016415 Sequence Alignment The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms. Sequence Homology Determination,Determination, Sequence Homology,Alignment, Sequence,Alignments, Sequence,Determinations, Sequence Homology,Sequence Alignments,Sequence Homology Determinations
D017354 Point Mutation A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair. Mutation, Point,Mutations, Point,Point Mutations
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
February 2007, Antimicrobial agents and chemotherapy,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.
April 1993, Journal of virology,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.
October 1991, Proceedings of the National Academy of Sciences of the United States of America,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
Simian immunodeficiency virus reverse transcriptase. Purification and partial characterization.
August 1990, European journal of biochemistry,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
December 1991, Proceedings of the National Academy of Sciences of the United States of America,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
March 2009, Pharmacotherapy,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors.
May 1993, Antimicrobial agents and chemotherapy,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
Nonnucleoside reverse transcriptase inhibitors.
October 1997, AIDS clinical care,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
December 2004, Antimicrobial agents and chemotherapy,
Y Isaka, and S Miki, and S Kawauchi, and A Suyama, and H Sugimoto, and A Adachi, and M Hayami, and O Yoshie, and T Fujiwara, and A Sato
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1.
December 1999, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!